Memorial Sloan Kettering Study Reports Increase in Mesothelioma in Younger, Female Patients

A just-released study from researchers at New York’s Memorial Sloan Kettering Cancer Center has revealed an alarming trend of diagnoses in patients under age 50, particularly among younger women with no self-reported history of asbestos exposure. The study’s authors urge physicians to familiarize themselves with the symptoms of the rare form of cancer and consider

UK Family Secures Five-Figure Mesothelioma Settlement from Ford

A family in the United Kingdom has secured a five-figure mesothelioma settlement following the death of their father, a longtime Ford production worker. The man died from the asbestos-related cancer months after being diagnosed, and his exposure was traced to asbestos-lagged pipes at Ford’s Dagenham and Basildon manufacturing facilities. He’d worked at the facility for

Gold Bond Talc Products and Asbestos

Gold Bond has been one of America’s most recognized medicated powder brands since the company’s founding, back in 1908. For most of its history, Gold Bond powders relied on talc as a primary ingredient. Unfortunately, talc and asbestos deposits are frequently adjacent, and that led to many talc-based products — including Gold Bond — being

The Discovery Process in Mesothelioma Lawsuits

Though every mesothelioma lawsuit is different, attorneys follow a standard process to ensure the best possible outcome. One of the most important phases of litigation is discovery. This pre-trial period involves the gathering and exchange of information between all parties. A thorough discovery process can make all the difference in whether your case settles out

How Artificial Intelligence Is Changing Mesothelioma Care

Artificial Intelligence is revolutionizing many aspects of life, including how doctors approach mesothelioma diagnosis, treatment, and patient care. Advanced computational technologies are improving diagnostic accuracy, speeding up investigational processes, and personalizing treatment approaches. From predicting patient outcomes to discovering novel therapies, AI is transforming mesothelioma care in ways that were unimaginable just a few years ago and

Pembrolizumab-Lenvatinib Combination Delivers 60% Response Rate in Mesothelioma Patients

Mesothelioma patients whose disease progressed after receiving a first-line treatment of nivolumab plus ipilimumab achieved a 60 percent objective response rate when treated with second-line pembrolizumab plus lenvatinib therapy. Dutch researchers report that twenty patients experienced a median progression-free survival of 6.9 months and disease control rates of 90 percent at 3 months and 52.6

Mesothelioma Risk Resurfaces as Asbestos is Discovered in Wind Turbine Brake Components

Mesothelioma has long been categorized as an occupational disease, as many industries historically put workers at risk of asbestos exposure. Despite efforts to eliminate the use of the toxic mineral, new concerns have been raised after chrysotile white asbestos was discovered in brake pads used in wind turbines at Goldwind Australia’s Cattle Hill Wind Farm

Get Help Contacting Mesothelioma.net
This field is for validation purposes and should be left unchanged.
24/7 Live Chat
Online Now